The Demand
How it's sold now: the market that can't say its own name
The forum era had a shape you could draw: a message board, a “research chemical” website, a parcel. The influencer era explained what happened to the product’s image — the spray, the flavours, the vacation-peptide voice. This file is about the machinery underneath the image. Not why people want it; the rest of this pillar covers that. Not what regulators did about it; the enforcement file is that ledger. This is the supply side as it actually operates: how a compound that is approved nowhere, and that most of its own sellers will not name, moves from a factory to a checkout to a nostril.
The short version is that Melanotan II is now sold through a complete, modern, direct-to-consumer retail stack — storefront, marketing channel, commissioned salesforce, physical counter, payment rails — and every layer of that stack has learned the same trick. When pressure lands, the molecule stays and the costume changes.
The storefront wears a lab coat
The oldest costume is still the load-bearing one. The dedicated websites that sell Melanotan II — and there are many — overwhelmingly present as suppliers of research chemicals: vials “for laboratory use only,” “not for human consumption,” no dosing instructions on the page because officially there is no one to dose. The disclaimer is the business model. It is an attempt to step outside the definition of a drug at the exact moment of sale, and the three-doors primer explains why regulators read it differently: a tanning peptide sold retail, one vial at a time, to the general public, is not research supply in any sense a laboratory would recognise.
What is new is the measured scale. In December 2025, LegitScript — the firm that vets merchants for payment networks and advertising platforms — published the first dataset to track this market across ads, social media, and e-commerce at once, covering 2020 through 2025 and naming Melanotan alongside BPC-157, TB-500, PT-141, and the gray-market GLP-1 peptides. The numbers do not describe a niche under pressure. Advertisements for problematic peptides grew 208 percent from 2023 to 2024 — 678 percent from 2022. E-commerce marketplace sales grew 276 percent over five years. Social postings rose 75 percent in a year. The research-chemical costume is not a relic of the forum era. It is the storefront of a market in rapid expansion.
The shop window plays word games
The platforms did act. TikTok removed videos promoting and selling the product and banned the obvious hashtags — #melanotan, #melanotan2, #nasaltanningspray. On the platform’s own terms, that worked: the front door is closed.
The market’s answer was to stop using the name. LegitScript’s analysts describe the current marketing vocabulary as a set of deliberate near-misses: generically packaged “nasal tanning sprays” that never say melanotan; references to tanning “strengths”; the abbreviation MT2, or simply “2.” The images do the selling instead — deep tans, stark tan lines, before-and-after comparisons. When the Australian consumer group CHOICE investigated the local spray market, it found the videos skew deliberately young, because tan-line content performs with the algorithm and because the audience most susceptible to it is the one that hasn’t aged out of it. And it recorded the costume change happening in real time: after CHOICE asked one seller for comment, the seller’s website quietly dropped its claim that the product contained “MT2 Powder” — and then denied the product contained melanotan at all.
A hashtag ban is a filter on a word. This market has demonstrated, at platform scale, that it does not need the word.
The salesforce works on commission
The influencer layer is not just publicity; it is distribution with a compensation plan. The standard unit is a before-and-after clip plus a discount code or affiliate link, which means the person posting earns a cut of every sale their audience generates. That is a commissioned salesforce, in the exact sense a cosmetics multinational would use the term — except the product has no licence, the “brand” may be one person with a supplier relationship, and the sales pitch is a body.
The economics are worth stating plainly, because they explain the persistence. A bottle retails for roughly twenty to thirty pounds in the UK trade press’s accounting, and CHOICE found Australian sites charging around a hundred dollars. The contents of that bottle are a powder whose per-unit cost is trivial and whose actual identity, as Australia’s regulator proved by assay, may not match the label. The margin on an unregulated peptide in a flavoured spray is wide enough to pay a salesforce handsomely and still undercut nothing — because there is no legal competitor to undercut.
The counter is a salon drawer
The physical layer is the one enforcement keeps tripping over. The enforcement file documents the scene: reporters buying sprays over the counter in Manchester, Merseyside, and a Newcastle gym; a Welsh salon selling an unlabelled bottle while volunteering that the product was illegal; a seller who, asked what was in it, didn’t know. The UK’s Chartered Trading Standards Institute — the body that inherited the problem when the medicines agency said sprays without medical claims were not in its remit — put the retail picture on the record in May 2025: sprays, drops, and gummies, marketed through Facebook and TikTok, in flavours that read like a sweetshop inventory, with expert safety assessment “unlikely” and health warnings rare.
The salon counter matters because it completes the costume. A product bought in person, from a business with a chair and a till, does not feel like a gray-market drug. It feels like an upsell.
The checkout is where the disguise gets serious
The newest front is the least visible one, and it may be the most consequential. Payment networks police their merchants, and a merchant openly selling a banned drug loses the ability to take cards. LegitScript’s own enforcement history tells the story in two phases: from 2017 to 2021, melanotan merchants were flagged almost exclusively for blatant marketing of a banned product — they said what they sold. In the years since, its analysts have increasingly flagged the same trade as suspected transaction laundering: sellers whose products haven’t changed, but whose paper trail has — generic containers with the merchant’s own logo or no label at all, no ingredients list, storefronts and merchant accounts arranged so the payment looks like it is for something else.
That shift is the whole modern market in miniature. The 2010s seller hid from the medicines regulator. The 2020s seller hides from the payments system — because the payments system, unlike the regulator, can actually switch off the till. Whether it does so faster than the market can change costume is, on current evidence, an open race.
What a market this developed is telling us
Assemble the layers and the finding is uncomfortable in both directions. This is not a residual black market clinging on; it is a growth business with a full retail stack — measured in triple-digit percentages by the firm whose job is to watch it. Every layer has professionalised. The only thing the stack is missing is the one thing every legitimate DTC brand has: a product it is allowed to name.
That absence is the point, and it is why this file sits in the culture pillar and not the crime pages. A demand strong enough to sustain commissioned salespeople, salon distribution, and payment-system camouflage is the same demand this pillar has traced from the sun’s reward loop through a century of manufactured desire. The machine is sophisticated because the want is real. Enforcement can and should keep raising the cost of each costume — but a market that has survived takedowns, hashtag bans, border seizures, and merchant monitoring is not going to be dismantled layer by layer. It will be made obsolete, if it ever is, by a tested, legitimate agonist good enough that nobody needs a product that can’t say its own name. That remains this site’s stated opinion, and it is labeled as one.